乌司奴单抗剂量间隔缩短对克罗恩病的疗效
一项单中心回顾性研究纳入506例每8周接受乌司奴单抗90mg的克罗恩病患者,其中110例将间隔缩短至每4周。在基线有疾病活动证据的患者中,28%达到临床缓解,22%CRP正常,50%粪钙卫蛋白下降,36%达到内镜下缓解。
要点
- 乌司奴单抗90mg每8周应答不佳的CD患者,缩短至每4周可改善临床和生物學指标。
- 缩短间隔后28%达到临床缓解(HBI≤4),36%达到内镜下缓解。
- 剂量间隔缩短在研究中显示有效且安全。
核心结论
- 对每8周乌司奴单抗90mg应答不佳的克罗恩病患者,将剂量间隔缩短至每4周可改善临床和生物學疾病活动指标。
研究设计与样本
- 单中心回顾性研究,收集506例每8周皮下注射乌司奴单抗90mg的克罗恩病患者数据,其中110例将间隔缩短至每4周。
主要发现
- 在基线有HBI>4、CRP≥5mg/dL、粪钙卫蛋白>250μg/g或内镜证据的疾病活动患者中,缩短后28%达到临床缓解(HBI≤4),22%CRP正常(<5mg/dL),50%粪钙卫蛋白下降,36%达到内镜下缓解。
临床怎么用
- 对标准剂量乌司奴单抗每8周应答不佳的克罗恩病患者,可考虑将剂量间隔缩短至每4周。
局限性
- 为单中心回顾性研究,部分指标数据不完整(HBI 78例,CRP 60例,粪钙卫蛋白仅8例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: A subset of patients with Crohn's disease (CD) do not respond to ustekinumab at the standard dose of 90 mg every 8 weeks. Little is known about the efficacy of shortening the interval between doses. METHODS: We performed a retrospective study to determine the effectiveness of ustekinumab dose interval shortening, collecting data from 506 patients with CD who received subcutaneous ustekinumab 90 mg every 8 weeks at a single center. We obtained data from 110 patients who initially received subcutaneous ustekinumab 90 mg every 8 weeks and then had their interval shortened to every 4 weeks. Harvey Bradshaw Index (HBI) scores before and after the dose interval shortening was available for 78 patients in the cohort (71%), levels of C-reactive protein (CRP) for 60 patients (55%), and levels of fecal calprotectin for 8 patients (7%). RESULTS: Following dose interval shortening, the patients' median HBI decreased from 4.5 to 3 (P = .002), the median level of CRP decreased from 8 mg/L to 3 mg/L (P = .031), and median level of fecal calprotectin decreased from 378 μg/g to 157 μg/g (P = .57). Among patients who had an HBI >4, a level of CRP ≥5mg/dL, a level of fecal calprotectin >250ug/g, or endoscopic evidence for disease activity before dose interval shortening, after the dose interval was shortened, 28% achieved clinical remission (an HBI score ≤4), 22% had a normal level of CRP (<5 mg/dL), 50% had reduced levels of fecal calprotectin, and 36% achieved endoscopic remission. CONCLUSIONS: Shortening the ustekinumab 90 mg dose interval to 4 weeks for patients with CD who did not respond to doses every 8 weeks improved clinical and biological indices of disease activity. Patients who lose response to the standard dose of ustekinumab might benefit from dose interval shortening, which was effective and safe.
引用
- Ollech JE, Normatov I, Peleg N, et al. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32109634. doi:10.1016/j.cgh.2020.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。